Latest news with #L-Dopa
CBS News
26-02-2025
- Health
- CBS News
Pennsylvania professor concerned about Trump administration's plan to cut medical research funding
After growing concerns, a federal judge has put a temporary hold on the Trump administration's plan to reduce medical research funding. But the National Institutes of Health has lost jobs and there's a slow down on administrative actions. Doctors say millions of people take medications that resulted from years of research. And there are currently hundreds of potential new treatments in the pipeline. The pending research cuts have many worried, including a Montgomery County professor who depends on the research. Equations are always running through Michelle Francl-Donnay's mind at a Bryn Mawr College, where she's a chemistry professor. Francl-Donnay says her ability to move and work depends on a drug she takes for Parkinson's disease. Without it, she says writing a simple equation on a board would be impossible. The drug L-Dopa is the standard of care for treating the degenerative disease. "Without it, I would be disabled," Francl-Donnay said. "For me, it's really given me back my life." The drug is made from a molecule she admires, calling it magic. But it took years of research to develop. "Research isn't something where you know, oh, I'm gonna design a drug and make the molecule and I know automatically what this will do," she said. "It's sort of like wandering around and exploring new worlds." Those research worlds are bracing for funding cutbacks as the Trump administration wants to slash what White House spokesperson Kush Desai calls wasteful spending. "Contrary to the hysteria, redirecting billions of allocated NIH spending away from opaque administrative expenses means there will be more money and resources available for legitimate scientific research, not less," Desai said. Francl-Donnay disagrees. "We'll lose a whole generation of ideas and thoughts and drugs and treatments," Francl-Donnay said. She's angry about the pending research cuts that she thinks will impact millions of families. "Shingles, Crohn's disease, cancer, Parkinson's, Alzheimer's. The things that change lives are what's happening in these labs," she said. "Without it, we wouldn't have those treatments. And those touch really everybody." And it's not just treatments at stake, she's worried that life saving cures could be lost too. Understanding that science and medicine are complicated and advances take time, she's hoping time doesn't run out.
Associated Press
06-02-2025
- Business
- Associated Press
PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson's Disease
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the 'Company' or 'PreveCeutical'), announces a program aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Nose to Brain (N2B) Sol-Gel platform delivery technology. PreveCeutical's program is aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Sol-Gel N2B delivery technology. Extensive scientific research supports the provision of a steady, sustained dose of the neurotransmitter, or its precursor, to mitigate Parkinson's disease symptoms even at an advanced stage. PreveCeutical anticipates the safety and the effectiveness of the approach to be improved through avoidance of side effects stemming from systemic exposure, and a need for lower therapeutic doses due to direct brain targeting. Further information will be provided as the program is advanced. The Sol-Gel N2B delivery platform is designed to altogether bypass the Blood Brain Barrier (BBB), potentially improving drug bioavailability while reducing dose-related side effects associated with current drug delivery methods. The versatility of the N2B platform delivery system paves the way for delivering therapeutics to the brain without encountering the BBB and bypassing all other body compartments; these collective attributes have the potential to reduce drug dosages and side effects, improving patient compliance and clinical outcomes. Chairman and CEO Stephen Van Deventer commented. 'PreveCeutical's business model aims to develop cost-effective, preventive and curative therapies for patients globally. Once the program has successfully infused Dopamine and/or L-Dopa into the Sol-Gel platform, with PoC demonstrated in a preclinical model, we will explore partnerships with corporations and/or organizations who specialize in the field of Parkinson's disease'. About PreveCeutical PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector. With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs. For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook. On behalf of the Board of Directors of PreveCeutical Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact: Stephen Van Deventer: +1 604 306 9669 Or Investor Relations [email protected] Forward-Looking Statements: This news release contains forward-looking statements and forward-looking information (collectively, 'forward-looking statements') within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as 'will', 'pro forma', 'plans', 'expects', 'may', 'should', 'budget', 'schedules', 'estimates', 'forecasts', 'intends', 'anticipates', 'believes', 'potential', 'proposes' or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
Yahoo
06-02-2025
- Business
- Yahoo
PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson's Disease
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces a program aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Nose to Brain (N2B) Sol-Gel platform delivery technology. PreveCeutical's program is aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Sol-Gel N2B delivery technology. Extensive scientific research supports the provision of a steady, sustained dose of the neurotransmitter, or its precursor, to mitigate Parkinson's disease symptoms even at an advanced stage. PreveCeutical anticipates the safety and the effectiveness of the approach to be improved through avoidance of side effects stemming from systemic exposure, and a need for lower therapeutic doses due to direct brain targeting. Further information will be provided as the program is advanced. The Sol-Gel N2B delivery platform is designed to altogether bypass the Blood Brain Barrier (BBB), potentially improving drug bioavailability while reducing dose-related side effects associated with current drug delivery methods. The versatility of the N2B platform delivery system paves the way for delivering therapeutics to the brain without encountering the BBB and bypassing all other body compartments; these collective attributes have the potential to reduce drug dosages and side effects, improving patient compliance and clinical outcomes. Chairman and CEO Stephen Van Deventer commented. "PreveCeutical's business model aims to develop cost-effective, preventive and curative therapies for patients globally. Once the program has successfully infused Dopamine and/or L-Dopa into the Sol-Gel platform, with PoC demonstrated in a preclinical model, we will explore partnerships with corporations and/or organizations who specialize in the field of Parkinson's disease". About PreveCeutical PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector. With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs. For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook. On behalf of the Board of Directors of PreveCeutical Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact: Stephen Van Deventer: +1 604 306 9669Or Investor Relations ir@ Forward-Looking Statements: This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. To view the source version of this press release, please visit
Associated Press
27-01-2025
- Health
- Associated Press
With significant clinical results published in the Nature Medicine Journal, InBrain Pharma is about to durably modify the advanced Parkinson's disease management
A World Premiere in Parkinson's Disease With significant clinical results published in the Nature Medicine Journal, InBrain Pharma is about to durably modify the advanced Parkinson's disease management A breakthrough therapeutic approach for Parkinson's disease: Anaerobic dopamine brain infusion 1 Lille, January 27, 2024 – InBrain Pharma, a clinical stage biotech specialized in therapeutic solution development against neurodegenerative diseases , is thrilled to announce the publication of the outstanding results of the Phase I/II DIVE-I monocentric study conducted at the Lille University Hospital in the Nature Medicine Journal. This article, titled 'Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trial 2,' deals with a revolutionary therapeutic approach : A continuous and personalized brain infusion of dopamine thanks to an innovative galenical formulation & the invention of a new route of administration A therapeutic breakthrough that will likely result in revisiting the today management guideline of advanced Parkinson's disease For nearly 60 years, direct delivery of dopamine to the brain was deemed as impossible after the failures of Teams of Dr. Horn in Melbourne, Dr. Mark in Boston, and Dr. Fahn in New York during the 1980s. The rapid oxidation of the chemical entity had rendered the attempt unsuccessful. InBrain Pharma has overcome two major technological hurdles: stabilizing the chemical entity of dopamine and ensuring its controlled, continuous delivery in situ near the striatum, the brain area becoming depleted in dopamine over time. These two combined achievements made possible the brain infusion of a deficient neurotransmitter, correcting symptoms of a neurological disorder into which the neurotransmitter plays a central role. This invention is that of Professors David Devos and Caroline Moreau, with the support of their teams at the University of Lille, the Lille University Hospital, INSERM and at InBrain Pharma, of which they are co-founders and scientific advisors. Direct access to the brain to introduce the missing neurotransmitter at the right dose in the right place - close to the striatum - marks a decisive turning point in the therapeutic management of Parkinson's disease and will most likely lead to a revision of the disease treatment guidelines as we learn more about how this new therapeutic approach can benefit Parkinson's patients. This therapeutic breakthrough now enables a pharmacological neuromodulation of dopaminergic receptors by a personalized, continuous and circadian delivery of deficient dopamine directly to the brain of patients suffering from advanced Parkinson's disease with severe and refractory late complications related to L-Dopa treatment3. Professors Devos and Moreau, who were also nominated last summer for the European Inventor Award 2024, are writing a new chapter in the modern history of science, by introducing personalized medicine into the management of a neurodegenerative disease, and opening up a whole new field of exploration and hope in the fight against other diseases affecting the brain (other neurodegenerative, neurometabolic, neurooncological diseases, etc.). An innovative therapy to compensate for dopamine deficiency with personalized titration Parkinson's disease, which progressively destroys the dopaminergic neurons essential for the automatic control of movement, cognition and emotion, affects more than 9 million people worldwide. Its motor symptoms, such as akinesia, muscle rigidity and tremors, appear when more than 50-70% of dopaminergic neurons are destroyed. Although L-Dopa remains the reference treatment today, its efficacy diminishes over time. Invasive treatment options - known as device-assisted therapies (DATs) - being either non-drug-based, such as electrodes for deep brain stimulation, or drug-based, with L-dopa or related drugs associated to external pumps for continuous subcutaneous or enteral infusion, are available to increase central bioavailability of L-dopa and greater conversion to dopamine. However, the DAT's use remains limited. Only a third of advanced-stage patients has been treated with them. Therapeutic management at this stage of the disease therefore calls for new approaches to relieve the two-thirds of Parkinson's patients who are left without any solutions, and who remain on oral therapy with an inadequate motor symptom control. InBrain Pharma's innovative therapy by restoring the dopamine brain level in Parkinson's patients by continuous cerebral perfusion will help meet this pressing need for new therapeutic offerings. Promising results from the DIVE-I phase I/II study The DIVE-I study comprising two phases, a phase I to assess feasibility and safety, and a phase II assessing the efficacy and the safety of A-dopamine4 showed: 1. An improved motor symptom control: Significant reduction in overdosing (dyskinesia) or underdosing (bradykinesia) compared to optimized oral Parkinson's treatment. An average gain of 4.4 hours of 'ON' time (perfect motor control) without dyskinesia. An average gain of 6.6 hours of functional autonomy per 24-hour period. 2. A reduction in oral dosage: A 60% decrease in daily L-Dopa equivalent dosage due to continuous A-dopamine administration. 3. An Excellent safety profile: No serious adverse events related to A-dopamine. Transient and expected side effects, such as nausea, similar to oral L-Dopa treatments. Significant reduction in L-Dopa-related dyskinesia. 4. Patient satisfaction: All patients having completed Phase II chose to continue treatment in the study long-term follow-up phase. ' These initial results underline the full potential of this new dopamine-based device-assisted therapy (DAT), which promises to be the best representative of the DAT class in the long term, offering an alternative not only to patients who have failed current therapies, but also to those who are not considering treatment with available DATs. In addition to demonstrating the benefits for Parkinson's disease, this work also validates the concept of cerebral infusion as a personalized treatment for other neurological pathologies,' state Professors Devos and Moreau, neurologists at Lille University Hospital, University of Lille and INSERM, and co-founders and scientific advisors of InBrain Pharma. ' Given the major therapeutic progress and public health impact to expect from this dopamine-based DAT showing a fully different activity profile from that of L-dopa-or related drug based DATs, we are doing our utmost to confirm these results as quickly as possible on a larger scale, with a Phase III program that will guarantee the fastest possible market access by the end of this decade under early accesses, and by the very beginning of the next decade for a full access ', concludes Dr Véronique Foutel, CEO of InBrain Pharma. A major medical breakthrough to enhance patient quality of life In the 21st century, medical priorities have evolved due to the decline in mortality and the increase in life expectancy, leading to greater focus on morbidity and quality of life. The goal is no longer merely to extend life but to improve patients' physical condition and autonomy, especially in the context of disabling chronic diseases. Dopamine supplementation in the treatment of Parkinson's disease aligns with this approach of reducing the burden and consequences of a highly disabling illness and should remain an essential therapeutic strategy regardless of future innovations in the field. Following the era of hormonal supplementation aimed at correcting symptoms caused by endocrine secretion deficits, a new era of personalized central supplementation with deficient neurotransmitters is emerging to address medical disorders. About InBrain Pharma InBrain Pharma, a biopharmaceutical company, created in 2018, exploits through a worldwide exclusive patent license signed with SATT Nord, a novel therapeutic approach to Parkinson's disease based on the research work of Prof. David DEVOS and Prof. Caroline MOREAU in their academic research team at the University of Lille, Lille Neuroscience & cognition UMR-S 1172 INSERM and Lille University Hospital. In July 2024, Professors Devos and Moreau were finalists in the Research category of the European Inventor Award 2024 organized by the European Patent Office. InBrain Pharma was also a winner of the University of Lille Foundation Prize, the i-Lab competition, and received Deeptech support.
